With launches on the way in the US and EU, MC2 turns attention to the rest of its pipeline

Over the next 12 months, MC2 Therapeutics will start three new clinical studies with the follow-up drugs to Wynzora, which will soon be launched in the US and Europe.

Photo: MC2 Therapeutics / PR

The launch of psoriasis drug Wyzora alongside Epi Health marks the beginning of a new era for MC2 Therapeutics.

The biotech firm, which recently founded its own organization in the US, wants to expand its product range. This is why it has worked on several drug candidates alongside the development of Wynzora, products the company can now allocate more resources to, says Jesper J. Lange, CEO of MC2 Therapeutics.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs